GH Research (NASDAQ:GHRS) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

GH Research (NASDAQ:GHRSGet Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06, Zacks reports.

GH Research Price Performance

GHRS traded down $0.08 during midday trading on Friday, hitting $10.58. 38,957 shares of the company’s stock traded hands, compared to its average volume of 636,491. The company has a market cap of $550.20 million, a PE ratio of -13.37 and a beta of 0.93. The stock’s fifty day simple moving average is $10.44 and its 200-day simple moving average is $9.20. GH Research has a one year low of $6.00 and a one year high of $20.50.

Analysts Set New Price Targets

A number of equities research analysts have commented on GHRS shares. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of GH Research in a research report on Monday, January 27th. Canaccord Genuity Group decreased their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th. Cantor Fitzgerald began coverage on shares of GH Research in a research report on Thursday, February 13th. They set an “overweight” rating and a $14.00 price objective on the stock. Finally, Stifel Nicolaus increased their target price on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, GH Research has a consensus rating of “Buy” and a consensus target price of $30.60.

Check Out Our Latest Stock Analysis on GH Research

GH Research Company Profile

(Get Free Report)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Featured Stories

Earnings History for GH Research (NASDAQ:GHRS)

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.